KCM
ZVRA icon

Kennedy Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Kennedy Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,445
Closed -$799K – 751
2016
Q1 		$799K Buy
3,445
+325
+10% +$78.7K 0.02% 675
2015
Q4 		$991K Buy
3,120
+899
+40% +$244K 0.02% 659
2015
Q3 		$689K Buy
+2,221
New +$680K 0.01% 676

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Kennedy Capital Management's ZVRA Position: Q2 2016 in Review

Kennedy Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 3,445 shares — an estimated $799K sold.

Kennedy Capital Management first reported a position in ZVRA in Q3 2015 and held it in 3 quarters. The position peaked at $991K in Q4 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Kennedy Capital Management reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Kennedy Capital Management sold 3,445 Zevra Therapeutics shares in Q2 2016, an estimated $799K.
  • Kennedy Capital Management first reported a position in Zevra Therapeutics in Q3 2015 and held it in 3 quarters.
  • Kennedy Capital Management's Zevra Therapeutics position peaked at $991K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Kennedy Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.